News in Numbers

AstraZeneca signed a definitive agreement to acquire rare endocrine disease specialist Amolyt Pharma for $1.05bn in March.

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has already awarded 13 positive opinions on new medicines this year, as per a February 2024 update.

GlobalData’s patient-based forecasts estimate that Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first-ever therapy approved to treat noncirrhotic nonalcoholic steatohepatitis (NASH), will earn $1bn in 2027.

As per a new study highlighted by the World Health Organization, more than 3 billion people were living with a neurological condition in 2021.

After news of Amylyx Pharmaceuticals’ Phase III trial for its amyotrophic lateral sclerosis (ALS) therapy Relyvrio (sodium phenylbutyrate and taurursodiol) failing to meet any of its endpoints broke, the company’s stock opened at an 85.7% drop compared to the previous day.